✨ Free AI Report
Assertio Holdings, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Assertio Holdings, Inc.
Company Research

Assertio Holdings, Inc.: Business Overview, Financials & Competitive Analysis

Assertio Holdings, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Undervalued specialty pharma company with streamlined portfolio, profitable operations, and fortress balance sheet positioned for growth acceleration. Trading at a price-to-cash ratio of 0.72 and price-to-EBITDA multiple of 6.5x, ASRT is trading at a discount to historical averages and industry peers. The company has resolved major legal liabilities reducing.

What is Assertio Holdings, Inc.'s industry? Assertio Holdings, Inc. (assertiotx.com) operates in Specialty Pharmaceuticals. AskCyborg classifies Assertio Holdings, Inc. under Specialty Pharmaceuticals in its company registry.

Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients with a robust portfolio of branded prescription neurology, inflammation, pain and oncology medications. In the volat...

7/ 10Strong

Cyborg Score thesis

Undervalued specialty pharma company with streamlined portfolio, profitable operations, and fortress balance sheet positioned for...

Read the full analyst-debate transcript →
Industry Specialty Pharmaceuticals
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Assertio Holdings, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Assertio Holdings, Inc.

AskCyborg analysts argue the bull and bear cases for Assertio Holdings, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Assertio Holdings, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Assertio Holdings, Inc. Overview

Pro stress-test →

Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients with a robust portfolio of branded prescription neurology, inflammation, pain and oncology medications. In the volatile world of specialty pharmaceuticals where generic competition and regulatory headwinds often erode margins, Assertio has emerged as a rare success story with strategic transformation, earnings outperformance, and a fortress-like balance sheet.

Strategic Profile

Pro stress-test →

The company has pivoted from a cost-cutting exercise to a growth-oriented strategy by exiting non-core assets and doubling down on high-margin products. Key products Rolvedon and Sympazan saw sequential sales increases of 20% and 18.5% respectively in Q2 2025.

Competitive Landscape

Pro stress-test →

As a specialty pharmaceutical company in neurology, hospital, and pain and inflammation markets, Assertio competes against larger pharma companies like Pfizer, AbbVie, and smaller specialty players including Collegium Pharmaceuticals, Akebia Therapeutics, and Ironwood Pharmaceuticals. The company differentiates through a focused portfolio of branded generics targeting high-margin chronic condition indications.

Industry Context

Assertio Holdings, Inc. operates in Specialty Pharmaceuticals.

Key facts

Founded: 1995 · Headquarters: Lake Forest, Illinois · Revenue: $28.8M · Market cap: $79.4M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Assertio Holdings, Inc..

  • Company streamlined operations by exiting OTREXUP while doubling down on Rolvedon and Sympazan, which showed strong sequential growth in 2025.
  • Market cap of $70 million is dwarfed by $98.2 million cash reserves, indicating significant cash coverage.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025Filed certificate of amendment to incorporation; narrowed FY25 adjusted EBITDA guidance to $14M-$16M
  • November 2025Reported Q3 2025 earnings beat with $1.65 EPS significantly above consensus
  • +1 moreTrack every material event for Assertio Holdings, Inc. as it happens. Explore monitoring →
Get alerted when Assertio Holdings, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Neurology & Pain ProductsLarge-cap pharma with broad neurology portfolio→Specialty Pain ManagementSpecialty pharma focused on pain management→Rare Disease & SpecialtySmall-cap specialty pharma competitor→

Compare Assertio Holdings, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Assertio Holdings, Inc. operates in Specialty Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Top companies in Specialty Pharmaceuticals by Cyborg Score

Browse Specialty Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Assertio Holdings, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Assertio Holdings, Inc. and its top competitor on Cyborg Score”
“What did Assertio Holdings, Inc. do this quarter?”
“Is Assertio Holdings, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Assertio Holdings, Inc. do?+
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients with a robust portfolio of branded prescription neurology, inflammation, pain and oncology medications. In the volat...
What is Assertio Holdings, Inc.'s Cyborg Score?+
Assertio Holdings, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Assertio Holdings, Inc.'s main competitors?+
Named competitors include Neurology & Pain Products, Specialty Pain Management, Rare Disease & Specialty. The full competitive landscape is in the AskCyborg report.
How can I get the full Assertio Holdings, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Assertio Holdings, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Assertio Holdings, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Specialty Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Catalyst Pharmaceuticals, Inc.7Achieve Life Sciences, Inc.7Viatris Inc.7Xeris Biopharma Holdings, Inc.6Allergy Therapeutics PLC6Eagle Pharmaceuticals Inc.6Santhera Pharmaceuticals Holding AG6Supernus Pharmaceuticals, Inc.5Amphastar Pharmaceuticals, Inc.5Animalcare Group PLCTop companies in Specialty Pharmaceuticals by Cyborg Score